Core Viewpoint - Inokang Medical Technology (Suzhou) Co., Ltd. has initiated the listing guidance process with Huatai Securities, marking a significant step towards its public offering in the high-end medical device sector [1][2] Company Overview - Inokang was founded in 2014 by a team of overseas returnees and experienced professionals in the domestic medical industry, headquartered in Suzhou, Jiangsu, with production bases in Hefei and a research center in California, USA [1] - The company focuses on high-end medical devices, including ultrasound energy platforms, electrosurgical energy platforms, ophthalmic instruments, and minimally invasive surgical robots, emphasizing core technology innovation and intellectual property protection [1] Technological Platforms - Inokang concentrates on three main technology platforms: - Ultrasound energy platform for soft tissue cutting and hemostasis devices - Electrosurgical energy platform for minimally invasive surgery - Ophthalmic instruments and surgical robots, including cataract ultrasound emulsification systems, with products certified for international medical device standards [1][2] Market Achievements - The company has received the national-level "specialized and innovative small giant" enterprise title and has obtained multiple important medical device registrations domestically and internationally, with its ultrasound knife series products sold in over 70 countries and regions [2] - Inokang's products have achieved significant international certifications, including the Korean integrated ultrasound knife head registration certificate and the European MDRCE7MM certificate [2] Shareholding Structure - The controlling shareholder of Inokang is Liu Shougong, who directly holds 38.98% of the company's shares, while the actual controllers, Liu Shougong and Luo Wei, collectively control 65.87% of the company [2]